Biomineralized Polydopamine Nanoparticle-Based Sodium Alginate Hydrogels for Delivery of Anti-serine/Threonine Protein Kinase B-Rapidly Accelerated Fibrosarcoma siRNA for Metastatic Melanoma Therapy

ACS Nano, Год журнала: 2023, Номер 17(18), С. 18318 - 18331

Опубликована: Сен. 10, 2023

Malignant melanoma, as a highly aggressive skin cancer, is strongly associated with mutations in serine/threonine protein kinase B-RAF (BRAF, where RAF stands for rapidly accelerated fibrosarcoma). Targeted therapy anti-BRAF small interfering RNA (siBRAF) represents crucial aspect of metastatic melanoma treatment. In this study, an injectable hydrogel platform based on sodium alginate (SA), multifunctions photothermal and Ca2+-overload cell apoptosis, was explored siBRAF carrier therapy. We employed polydopamine nanoparticles (PDAs) core constructed calcium phosphate (CaP) shell via biomineralization (PDA@CaP) to load (PDA@siBRAF/CaP). The pH-sensitive CaP facilitated the release Ca2+ under weakly acidic tumor microenvironment, triggering gelation PDA@siBRAF/CaP-SA localized at sites interruption RAS-RAF-MEK-ERK (MAPK) pathway. Besides, continuous could also lead apoptosis. Moreover, effect PDA regulated kinetics, resulting coordinated therapeutic abilities individual components hydrogels. Consequently, effective inhibition growth metastasis achieved vitro vivo using line B16F10 model, by combining ablation, overload, BRAF silencing. Our work provides proof-of-concept system that simultaneously targets multiple mechanisms involved progression has potential be translated into clinical use

Язык: Английский

---

Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017

Journal of Cancer Research and Clinical Oncology, Год журнала: 2024, Номер 150(1)

Опубликована: Янв. 1, 2024

Abstract Purpose Since the introduction of immune checkpoint inhibitors (ICI) and targeted therapies (TT), survival rates metastatic melanoma patients have increased significantly complete remissions are no longer rarities. Consequently, there is an increasing number long-term survivors who not yet been comprehensively characterized. Methods We included entered stage IV between 2014 2017 survived at least 5 years after entering IV. Descriptive statistics were performed to characterize applied systemic therapies, response report which these still alive today. Results 640 University Hospital Tuebingen. Of these, 207 (32%) Details available in 176 (85%). About 90% ( n = 159) time analysis. Median since first diagnosis was 6.0 (range 5–9 years). An impressive majority 146, 83%) receiving therapy evaluation. Complete remission under line seen 36% patients. Conclusion This dataset comprises largest cohort surviving our today, we expect future. Our data indicate need for specific follow-up programs addressing needs survivors.

Язык: Английский

---

Longer survival from melanoma in Germany

Deutsches Ärzteblatt international, Год журнала: 2024, Номер unknown

Опубликована: Янв. 16, 2024

New treatment options for cutaneous melanomas with a poor prognosis have been available since 2011, including immune therapies and targeted drugs. Randomized controlled trials demonstrated that these treatments improve survival, but no population- level studies to date.

Язык: Английский

---

Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden

British Journal of Dermatology, Год журнала: 2023, Номер 189(6), С. 702 - 709

Опубликована: Июль 18, 2023

Abstract Background Melanoma-specific survival (MSS) is heterogenous between stages and highly dependent on the T stage for primary localized disease. New systemic therapies metastatic cutaneous melanoma (CM) have been introduced since 2012 in Sweden. Objectives To analyse incidence MSS time trends 1990 2020 Methods Nationwide, population-based prospectively collected clinico-pathological data invasive CM from Swedish Melanoma Registry (SweMR) were analysed using Kaplan–Meier curves Cox proportional hazard ratios (HRs). Results In total, 77 036 CMs diagnosed 70 511 patients Sweden 2020. The 5-year [95% confidence interval (CI)] was 88.9% (88.3–89.4) 1990–2000, 89.2% (88.7–89.6) 2001–2010 93.0% (92.7–93.9) 2011–2020. odds being with nodular (vs. superficial spreading melanoma) significantly reduced by 20% (2001–2010) 46% (2011–2020) vs. reference period 1990–2000. Overall, improved over both diagnostic periods (2001–2010 2011–2020) 1990–2000 among men women, respectively [HRmen: 2001–2010: 0.89 (95% CI 0.82–0.96) 2011–2020: 0.62 0.56–0.67); HRwomen: 0.82 0.74–0.91) 0.56–0.70)]. risk of death lower all age groups women most recent (2011–2020 vs.1990–2000). Conclusions results emphasize improvements, specifically 2011–2020, may be correlated to introduction new are here shown first detail

Язык: Английский

---

Health indices for disease incidence risk and duration in the Semi-Markov setting

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Фев. 19, 2024

Over the last decade, number of years life lost (YLL) became a popular tool in biostatistics and epidemiology to measure discrepancies expectancy or mortality between cohort patients general population. Its prominence literature is primarily due its ease interpretation because information on cause death not required. Moreover, multi-state models are powerful statistical approach study evolution individuals several "states". Derived from data collected by Belgian Cancer Registry, encompassing 161,007 cases melanoma, thyroid, female breast cancer, three-state (healthy-cancer-death) illness-death model used illustrate how it can be applied cancer registry estimate incidence risk, at different ages diagnosis given that patient survived some after diagnosis. Results suggest probabilities being diagnosed with over next 20 for healthy individual remain rather low melanoma thyroid cancers both sexes, but considerably increases age cancer. also that, before 70 highest when young then decreases diagnosis, whereas cancers, peaks later (between 35 55 depending sex). It turns out larger men than women cancers. Last, found years, once they have their 10 remains below one year. This indicates up these lose limited compared

Язык: Английский

---

Exploration of organoids in ovarian cancer: From basic research to clinical translation

Translational Oncology, Год журнала: 2024, Номер 50, С. 102130 - 102130

Опубликована: Сен. 20, 2024

Язык: Английский

---

Positron emission tomography–computed tomography vs. brain magnetic resonance imaging for the detection of cerebral metastases of melanoma: a 5-year retrospective study

Clinical and Experimental Dermatology, Год журнала: 2024, Номер 49(10), С. 1179 - 1185

Опубликована: Апрель 16, 2024

Patients with melanoma present a high risk of developing extracutaneous metastases. Positron emission tomography--computed tomography (PET-CT) is one the preferred examinations for staging oncological patients. It not method choice to detect brain metastases, but this technique has shown significant improvement and allows detection some them. However, it unclear how performs compared magnetic resonance imaging (MRI), current gold standard diagnosing

Язык: Английский

---

Trends in incidence, mortality, and survival of cutaneous malignant melanoma over three decades: a population-based study in Southern Spain

Clinical and Experimental Dermatology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 22, 2024

Abstract Background Cutaneous malignant melanoma (CMM) represents a global public health problem. Epidemiological studies about CMM trends tend to focus on single indicators or lack information tumour characteristics that can help gain more thorough understanding of epidemiology. Objectives To fill this gap, we studied in incidence, mortality and survival over three decades considered sex, age characteristics. Methods Data were obtained for all patients with new diagnosis during 1985–2017 from the population-based cancer registry Granada (Southern Spain) deaths owing Ministry Health Spanish government. Incidence, estimates according group, anatomical site, histological type, Breslow index Clark level. Observed net calculated 1, 3 5 years using Kaplan–Meier Pohar–Perme methods, respectively. Log-linear jointpoint regression was used assess temporal age-standardized rates incidence mortality. Results Between 1985 2017, 2446 aged ≥ 15 newly diagnosed CMM. There significant increase both males females (annual percentage change 4.4% 3.7%, respectively), mainly superficial spreading nodular melanomas, pronounced among those < 1 mm index. Mortality increased, driven by increases individuals 65 old. Nodular had worst prognosis, 5-year 62.7% period 2008–2017 compared > 90% other subtypes. Overall improved 78.3% 1985–1997 88.6% 2008–2017, clear trend Conclusions The early stages Southern Spain has increased recent decades. This been accompanied noticeable improvements survival, especially younger groups, suggesting potential effectiveness prevention strategies treatment regimens.

Язык: Английский

---

Is the threat of malignant melanoma in the UK still increasing? A comprehensive analysis of 30 years of historical data and Bayesian age-period-cohort model projections for 2030

European Journal of Cancer Prevention, Год журнала: 2024, Номер unknown

Опубликована: Дек. 17, 2024

Malignant melanoma, a highly aggressive skin cancer, though less common, significantly contributes to cancer-related mortality. In the UK, it is of growing concern with an aging population, making crucial analyze historical trends and forecast future burdens. We used Joinpoint regression age-period-cohort models in incidence, prevalence, mortality malignant melanoma UK from 1990 2021. Bayesian model was applied predict disease burden for different age groups by 2030. From 1991 2021, incidence prevalence exhibited distinct temporal patterns: significant upward trend until 2015, particularly pronounced individuals aged 60 older, followed downward after 2015. By 2030, are projected decrease, younger middle-aged populations, expected fall 20.78/100 000 2020 11.90/100 000, 167.80/100 80.13/100 000. Mortality also decrease. However, high-risk groups, especially those 85 above, predicted maintain higher rates. Despite rise, have declined since 2015 continue declining through elderly population remains at risk, underscoring need targeted public health interventions.

Язык: Английский

---

Prognosis prediction and drug guidance of ovarian serous cystadenocarcinoma through mitochondria gene-based model

Cancer Genetics, Год журнала: 2024, Номер 292-293, С. 1 - 13

Опубликована: Дек. 29, 2024

Mitochondrial dysregulation contributes to the chemoresistance of multiple cancer types. Yet, functions mitochondrial in Ovarian serous cystadenocarcinoma (OSC) remain largely unknown.

Язык: Английский

---